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Abstract
Background
Novel biological therapies have revolutionised the management of Rheumatoid Arthritis (RA) but no cure
currently exists. Mesenchymal stem cells (MSCs) immunomodulate in ammatory responses through
paracrine signalling via growth factors, cytokines, chemokines and extracellular vesicles (EVs) in the cell
secretome; however, MSCs are still not available in the clinic. We evaluated the therapeutic potential of
MSCs-derived EVs in an antigen-induced model of arthritis (AIA).
Methods
EVs isolated from MSCs in normal (21% O2, 5% CO2) or hypoxic (2% O2, 5% CO2) culture or from MSCs
pre-conditioned with a pro-in ammatory cytokine cocktail were applied into the AIA model. Disease
pathology was assessed 3 days post arthritis induction through histopathological analysis of knee joints.
Spleens and lymph nodes were collected and assessed for T cell polarisation within the immune
response to AIA. Activated naïve CD4+ T cells from spleens of healthy mice were cultured with EVs or
MSCs to assess deactivation capabilities.  
Results
All EV treatments signi cantly reduced knee-joint swelling and histopathological signs of AIA with
enhanced responses to normoxic and pro-in ammatory primed EVs. Polarisation of T cells towards CD4+
helper cells expressing IL17a (Th17) was reduced when EV treatments from MSCs cultured in hypoxia or
pro-in ammatory priming conditions were applied.
Conclusions
Hypoxically cultured EVs present a priming methodology that is as effective in reducing swelling, IL-17a
expression, Th17 polarisation and T cell proliferation as pro-in ammatory priming. EVs present an
effective novel technology for cell-free therapeutic translation in treating in ammatory arthritis and
autoimmune disorders such as RA.
Background
Mesenchymal stem cells (MSCs) are a promising therapeutic option owing to their contribution to tissue
repair, regeneration and immunomodulatory properties. As well as potential for tissue repair through
trilineage differentiation capacity, MSCs in uence immune responses through immunomodulation
inhibiting T cell proliferation; disrupting B cell function and dendritic cell maturation; and promoting anti-
in ammatory responses mediated through macrophage interactions(1). Widespread introduction of stem
cell therapies has been hindered by the need to control and direct cell differentiation for tissue repair,
particularly where tissue regeneration is not the primary goal of therapy as in the case of autoimmune
disorders, such as Rheumatoid Arthritis (RA). For MSCs therapy, autologous bone marrow derived MSCs
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are harvested and expanded to achieve therapeutic cell numbers, raising concerns over use of diseased
donor cells and donor site morbidity due to invasive collection procedures, as well as potential variations
that may occur during in vitro cell expansion.
Our group has demonstrated the immunomodulatory capacity of both MSCs and their conditioned
medium (CM-MSC) to reduce in ammation in a murine antigen-induced arthritis (AIA) model(2, 3). MSCs
function through several mechanisms: cell-to-cell contact, paracrine signalling and autocrine
responses(1). CM-MSCs is rich in secreted paracrine signalling molecules and membrane bound vesicles
that can target the cells of the immune system. Collection of CM-MSC harnesses MSCs expression of
immunosuppressive factors which can be clinically applied in a therapeutic setting(4). Application of CM-
MSC bypasses the need to introduce live cell therapy and therefore reduces the risk of inappropriate cell
responses or unwanted tissue generation. CM-MSC is, however, not chemically de ned owing to the
complex cocktail of components secreted by cells during growth. The secretome of MSCs is high in
signalling molecules, such as TGF-β1, IL-10, CCL9, IFN-α, IFN-β, nitric oxide (NO), VEGF, FGF, HGF, PDGF
and membrane-bound vesicles(5). Extracellular vesicles (EVs) are lipid bilayer membrane bound particles
that convey a cargo of nucleic acid, including microRNA (miRNA), long non-coding RNA, mRNA and DNA,
lipid, carbohydrate and protein signals to facilitate intercellular communication(6–10). Notably,
circulating EVs have been linked to disease severity in seropositive RA(11–16). These particles are
typically < 1000 nm in diameter and can be subdivided by the mechanism of biogenesis. Exosomes are
EVs synthesised in late endosomes, also known as multivesicular bodies (MVBs), and released through
fusion of the MVBs with the plasma membrane, instead of being conveyed to the lysosome for
catabolism(10). Microvesicles are EVs generated through outward budding and  ssion of the plasma
membrane at locations enriched in speci c lipids and proteins(5, 10). In contrast to viable cell infusions
as therapy, EVs have no ability to replicate and their in uence on gene regulation is through mRNA, non-
coding RNAs and protein cargo(17). MSC-derived EVs have been shown to be bene cial in autoimmune
disorders in functioning to modulate autoimmune responses, particularly related to graft rejection and
hypertension(18–20) but also in in ammatory arthritis and rheumatic diseases(21–23). EVs are therefore
of particular interest in autoimmune disorders and have been examined extensively in their ability to
in uence cells of the immune system (dendritic, B, T cells and macrophages)(13, 16, 24). Furthermore,
secretion of EVs by immune cells can be induced through cell surface receptor activation and T cells have
been shown to recruit EVs released by dendritic cells, suggesting an integral action in orchestrating in
vivo immune responses(25, 26).
We previously demonstrated that the MSC secretome is responsible for the therapeutic effects of MSCs in
an antigen-induced model of arthritis(3). Here we test our hypothesis that MSC-derived EVs alone can
provide a valid alternative to MSC therapy overcoming major limitations which have prevented MSC
therapy into the clinic. By delivering signalling biomolecules in a target-speci c manner, EVs can in uence
cell responses in speci c tissues dependent upon their surface molecule expression pro le and can
therefore be selected to directly in uence speci c cell types or tissues integral to the disease state. EVs
can deliver their cargo into recipient cells through receptor-ligand interactions, direct fusion with the
plasma membrane, antigen presentation and endocytosis (24, 25). The therapeutic potential of EVs may
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be enhanced by manipulating their cargo to encourage therapeutic EVs to deliver a speci c or targeted
outcome, such as maximised anti-in ammatory capabilities(27, 28). The mechanisms by which cargo
selection is achieved in EVs is becoming less opaque with greater clarity on the composition of MVBs
and the interactions with the plasma membrane. Exosomes secreted by MVBs are sites for miRNA-loaded
RNA-induced silencing complexes (RISCs) and microvesicle protein cargo is re ective of the plasma
membranes of their generating cell type, suggesting that manipulation of the cell can directly lead to
adaptive EV cargo(25, 29–33).
It is therefore important to clearly de ne the means by which EVs can be selected and a method to
con rm positive identi cation. To standardise this process the International Society of Extracellular
Vesicles (ISEV) has generated ongoing guidelines for minimal requirements to de ne isolated particles as
EVs regardless of the selection methodology(34, 35). As the primary distinguishing feature of exosomes
and microvesicles is their biogenesis, not their size, we will here refer to all isolated particles as EVs and
eschew the terms exosome or microvesicle which remain contentious.
To date, no research has directly examined and contrasted the in uence of cell isolation and priming on
EVs generation using both hypoxia and pro-in ammatory pre-conditioning of MSCs during production.
Here we apply these methods and contrast with cell therapy, to determine the variations in
immunomodulatory properties, with a view to therapeutic application in autoimmune in ammatory
disorders. We present novel data relevant to the therapeutic potential of MSC-derived EVs utilising the AIA
model of in ammatory arthritis with direct comparison to the in uence of their parental MSC through
assessment of histological outcomes. We investigated the potential of primed MSCs using hypoxia and
pro-in ammatory preconditioning to assess the optimisation of EV production through treatment of cells
during EV production. The immunomodulatory action of primed MSC-derived EVs was investigated
through examination of T cell activation, differentiation and proliferation, and quanti cation of
immunomodulatory factors in comparison to EVs generated without MSC priming. We hypothesise that
EVs represent a potential therapeutic approach for the treatment of in ammatory arthritis that may
encounter less obstacles than cell therapy to widespread application in the clinic.
Methods
Cells and EVs
Primary human MSCs were isolated from commercially available bone marrow aspirate (Lonza, USA)
using an adherence technique(36) and cultured in normoxic (21%O2) or hypoxic (2%O2) conditions in
Dulbecco’s Modi ed Eagles Medium (DMEM) with 10% foetal bovine serum (FBS) and 1% penicillin-
streptomycin. Hypoxic cell culture was achieved using 2% O2 from isolation of MSCs from bone marrow
aspirate (Lonza) in hypoxic workstation (InvivO2 Physiological Cell Culture Workstation, Baker Russkin) to
ensure cells were not exposed to environmental oxygen levels at any stage of isolation or culture. Cells
(P3-P5) were characterised as MSC through immunophenotyping of surface markers with  ow cytometry
and tri-lineage differentiation(2). EVs were therefore isolated over a 48 hour culture period from MSCs in
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normoxic 21% oxygen culture (EV-NormO2); MSCs in hypoxic 2% oxygen culture (EV-2%O2) and from
MSCs previously cultured for 48 hours with pro-in ammatory cytokine cocktail comprising interferon-
gamma (IFN-γ, 10 ng/ml), tumour necrosis factor-alpha (TNFα, 10 ng/ml) and interleukin 1 beta (IL-1β,
5 ng/ml) prior to transfer to serum-free medium for 48 hours for EV collection (EV-Pro-In am).
Differential ultracentrifugation for isolation of EVs
MSCs from the same batch used for cell treatment (P3-P5) were cultured to 80–90% con uence in T75
 asks, washed with PBS three times and then serum-free DMEM. Flasks were incubated for 48 hours with
12 ml serum-free DMEM at 37 °C, 5% CO2. After 48 hours, conditioned medium (CM-MSC) was removed
and a cell count performed to determine the number of cells used to produce EVs. EVs were isolated from
CM-MSC by differential ultracentrifugation. In brief, CM-MSC was centrifuged for 10 minutes at 300 x g to
remove cell debris then again for 10 minutes at 2000 x g to remove apoptotic bodies and residual dead
cells. Supernatant was again taken and centrifuged at 10,000 x g for 45 minutes in an ultracentrifuge
(Beckman Coulter) to remove larger/denser EVs. Supernatant was again retrieved and passed through a
0.22 µM syringe  lter. Filtered supernatant was then centrifuged using 70.1Ti rotor (Beckman Coulter) in a
Beckman L8-55M ultracentrifuge at 100,000 x g for 90 minutes to isolate an EV pellet. EVs depleted
medium was removed and stored at -20 °C (EVs-depleted CM-MSC), whilst the visible EVs pellet was
resuspended in 5 ml of PBS to wash EVs and then spun again at 100,000 x g for 60 minutes, the
supernatant discarded and the residual EV pellet resuspended in PBS at 30µL per 1.0 × 106 cells used in
EV generation and stored at 4 °C to be used within 24 hours or at -20 °C for later use.
Characterisation of EVs
Successful isolation of EVs was con rmed through multiple methods in accordance with ISEV
guidelines(35). Samples of vesicle preparations underwent bicinchoninic acid assay (BCA Assay, Pierce
Biotechnology) for total protein concentration in EV preparations following manufacturer’s instructions
with EV disruption in a sonicating waterbath (30 seconds sonication at 1 minute intervals for 3 cycles) to
release intracellular protein and assess cargo proteins as well as surface proteins. Vesicles were
examined initially for expression of characteristic markers CD9, CD63 and CD81 (Miltenyi MACSPlex
Exosome Identi cation Kit, human) following manufacturer’s instructions for analysis. Particle by particle
analysis of vesicle size was assessed using Nanopore technology (Izon Science) tuned in the region ~ 
80–300 nm, to con rm the size fractions being applied experimentally.
Images of EVs were obtained using Transmission Electron Microscopy (TEM). EVs to be imaged by TEM
were isolated as detailed above, however residual EV pellet after PBS wash was resuspended in 30 µl
Milli-Q water per 3.0 × 106 cells. The resulting EV suspension was spotted onto a glow discharged holey
carbon mesh copper grids (Quantifoil, R2/1) and incubated at room temperature for 4 min 45 seconds
before 5µL of 0.22µ m  ltered 2% (v/v) uranyl acetate was added. This was left to incubate at room
temperature for a further 90 seconds before the excess liquid was removed using blotting paper. Grids
were then imaged using an FEI Tecnai G2 12 Biotwin (LaB6, accelerating voltage 100 kV).
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EV protein content was examined by Western Blotting to identify the presence of Alix and absence of
mitochondrial Cytochrome C (CYC1) in isolated particles, as per the minimal criteria for identi cation of
EVs(34). Brie y, ten micrograms of EVs and cells were lysed with 2x Laemlli buffer with β-
mercaptoethanol and denatured by heating at 70oC for 5 min. Samples were electrophoresed on a 4–12%
TGX stain free gel (Bio-Rad, CA, USA) at 200V for 30–40 min. Samples were then blotted onto a
nitrocellulose membrane using the wet transfer method overnight at 100V. After blotting, membranes
were blocked for 2 hours in 5% semi-skimmed milk in Tris-buffered saline with 0.05% Tween (TBST)
followed by an incubation in primary antibodies Alix (1:200), CYC1 (1:200) (Santa Cruz Biotechnology,
TX, US) for 2 hours at RT. After three  ve-minute washes, the membrane was probed with a goat anti-
mouse IgG-HRP conjugated secondary antibody (1:1,000 in TBST, Life Technologies Limited, Paisley, UK).
HRP-conjugated secondary antibody was added for 1 h and the wash step repeated. SuperSignal West
Femto Chemiluminescent Substrate (Thermo Fisher Scienti c, Waltham, MA, USA) was added to the
membrane and imaged with ChemiDoc™ Touch Imaging System (Bio-Rad, CA, USA) using Image Lab
v.6.0.1 software (Bio-Rad, CA, USA).
Antigen-induced arthritis (AIA) model of in ammatory
arthritis
Animal procedures were undertaken in accordance with Home O ce project licence PPL40/3594. AIA
was induced in male C57Bl/6 mice (7–8 weeks) as previously described(2, 3, 37). Swelling was assessed
by measuring the difference in diameter between the arthritic (right) and non-arthritic (left) knee joints (in
mm) using a digital micrometer (Kroeplin GmbH) before and at set time points after treatment with PBS
(control), EVs or EV-depleted CM-MSC.
Intra-articular injection of MSC and EVs
Treatments were 15 µl of EVs suspension corresponding to EV secretions from ~ 5.0 × 105 cells or EV-
depleted CM-MSC (basal medium using serum free DMEM). Treatments or PBS vehicle control were
injected intra-articularly 1 day post arthritis induction with 0.5 ml monoject (29G) insulin syringes (BD
Micro-Fine, Franklyn Lakes, USA) through the patellar ligament into the right knee joint. Joint diameters
were measured at 1, 2 and 3 days post injection. Blood, joints, spleen, inguinal and popliteal lymph nodes
were collected immediately post-mortem. Three independent experiments were performed. All measures
were taken to reduce animal numbers (n = 6–21 per condition).
Arthritis Index
Animals were sacri ced for histological analysis at day 3 post arthritis induction. Joints were  xed in 10%
neutral buffered formal saline and decalci ed in formic acid for 4 days at 4 °C before para n
embedding. Sections (5 µm) were stained with haematoxylin and eosin (H&E) and mounted in
Hydromount (National Diagnostics) as described previously(2, 3). H&E sections were scored for
hyperplasia of the synovial intima (0 = normal to 3 = severe), cellular exudate (0 = normal to 3 = severe)
and synovial in ltrate (0 = normal to 5 = severe) by two independent observers blinded to experimental
groups(38). Scores were summated, producing a mean arthritis index.
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Cytokine Quanti cation.
IL-10 and TNFα in serum and CM-MSC were quanti ed using mouse Quantikine ELISA IL-10
immunoassay (R&D Systems) and TNFα ELISA high sensitivity (eBioscience) respectively, following
manufacturer’s instructions.
T cell polarisation
Spleens and lymph nodes (popliteal/ inguinal) were collected from mice 3 days post-arthritis induction
and dissociated as described previously(3). Splenocytes and pooled lymph node cells were seeded
separately at 1.0 × 106 cells/well in 96-well plates (Sarstedt) in RPMI-1640 with 10% FBS, 0.05 µg/mL IL-2
and activated with cell stimulation cocktail (eBioscience) for 1 hour prior to adding 10 µg/ml brefeldin A
(Sigma) and culturing for a further 4 hours. Unstimulated T cells and cells without brefeldin A served as
negative controls. Following activation, cells were resuspended in 2 mM EDTA in PBS and Tregs (CD4 + 
CD25 + FOXP3+) were isolated using the CD4 + CD25 + Regulatory T Cell Isolation Kit (Miltenyi) following
manufacturer’s instructions; or stained for T cell subset identi cation. For this, cells were permeabilised
using permeabilisation buffer kit (eBioscience) and intracellularly stained with anti-mouse IFN-γ (Th1), IL-
4 (Th2) or IL17a (Th17) (eBioscience). Cells were analysed on a BD FACS Canto II  ow cytometer and
comparisons drawn for percentage CD4 + cells and signal intensity (XGeoMean) for each antibody.
Co-culture of T cells with MSC/CM-MSC
Proliferation of activated T cells was assessed as a measure of T cell deactivation. Initially, for positive
controls 5 × 104 MSCs were cultured in 96-well plates for 24 hours at 37 °C. CD4 + T cells were puri ed
from spleens and lymph nodes (popliteal/inguinal) of healthy C57Bl/6 mice using the CD4 + T Cell
Isolation Kit (Miltenyi) following manufacturer’s instructions. T cells were seeded at a density of 5.0 × 
105/well in 250 µl RPMI medium with 10% FBS and cultured for 5 days with MSCs (ratio 10:1) or with EV-
NormO2, EV-2%O2 or EV-Pro-In am (ratio equivalent to secretions from 10:1 cells) (n = 8). T cells alone
served as control. Cells were activated using anti-Biotin MACSiBead Particles (Miltenyi) (ratio 2:1). EV
treatments were refreshed after 2 days of culture. Polarisation was assessed as above and proliferation
measured through reduction in signal intensity using VPD450 Violet proliferation dye (BD Biosciences)
(3).
Statistical analysis
Data were tested for equal variance and normality using D'Agostino & Pearson omnibus normality test.
Differences between groups were compared using 1-way ANOVA for parametric data or Kruskall-Wallis
ANOVA for non-parametric, or 2-way ANOVA with Bonferroni correction, as stated. All statistical analysis
was carried out using Prism 5 (GraphPad software) or IBM SPSS Statistics 24.0, with P < 0.05 deemed
statistically signi cant. Results are expressed as mean ± con dence interval.
Results
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EVs isolated via differential ultracentrifugation meet ISEV
criteria
All EVs isolated in this study underwent a  nal 100,000 x g ultracentrifugation, a step that allows
enrichment in small EVs. EV pellets were resuspended in a volume of PBS equivalent to 30 µl per 1.0 × 
106 EV-secreting MSCs. Three distinct types of EV preparations were generated by culturing MSCs under
normoxia (referred to as EV-NormO2; n = 11), hypoxia (referred to as EV-2%O2; n = 4) and pro-
in ammatory conditions (referred to as EV-Pro-In am; n = 4), were used here as treatment both in vitro
and in vivo.
A combination of quantitative and qualitative analyses were performed to con rm the presence of EVs
and characterise their properties in EV-NormO2 preparations. Firstly, enrichment in characteristic exosome
markers CD9, CD63 and CD81 in EV preparations from MSCs cultured under normoxic conditions was
assessed by  ow cytometry analysis using the MACSPlex exosome kit. This technology allows
identi cation of 37 exosomal surface epitopes separated into individually identi able populations using
FITC and PE conjugation, then assessment of the percentage of epitope expression is achieved using
APC conjugation for all epitopes within their individual populations. EV isolations showed elevated
enrichment in CD9 (81.25 ± 5.03%), CD63 (94.59 ± 2.23%) and CD81 (79.41 ± 9.07%) (n = 11) (Fig. 1A)
con rming the isolation of exosome enriched EVs. Secondly, western blot analysis of MSC lysate and EVs
(EV-NormO2) for detection of Alix, a protein involved in MVB biogenesis, and cytochrome C, an ubiquitous
mitochondrial protein acting as negative control, showed that isolated MSC-EVs are highly enriched in
Alix, which is expressed by their cells of origin, but do not contain cytochrome C as expected (Fig. 1B).
Thirdly, EVs were characterised for their size distribution and concentration using the Nanopore
technology (Izon). EVs preparations showed a distribution of EV sizes with most prevalent diameter of ~ 
200 nm with maximal diameter ~ 500 nm (Fig. 1D-E). Finally, TEM imaging demonstrated the presence of
spherical vesicles in isolated preparations in accordance with ISEV criteria for single EVs characterisation
(Fig. 1F). Together, these results demonstrate isolation of EVs meets ISEV criteria, con rming the
presence of MSC-derived vesicles which can be con dently applied to our study.
MSC priming increases total protein content in EV cargo
Several cell priming approaches have been evaluated that enhance the anti-in ammatory,
immunosuppressive, immunomodulatory, and regenerative properties of MSCs in order to increase their
therapeutic e cacy. Here, we investigated the effect of MSC priming with hypoxia and in ammatory
cytokines on EV secretion. As cell priming induces cell activation, molecular signalling, genetic or
epigenetic modi cations, and changes to cell morphology and phenotype, all of which involve changes in
protein expression, we set out to determine whether the total protein content in the cargo of EVs was
impacted by cell priming. A BCA assay revealed a trend for increased protein in EV-2%O2 preparations
(81.29 ± 34.82 pg/1.0 × 106 cells; n = 8) and EV-Pro-in am (69.09 ± 37.38 pg/1.0 × 106 cells; n = 9)
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compared to EV-NormO2 (40.43 ± 14.73 pg/1.0 × 106 cells; n = 11) that was not statistically signi cant (p 
> 0.05) (Fig. 1C).
Application of MSC-derived EVs ameliorates histopathology
and clinical symptoms of AIA
AIA is an acute model of in ammatory arthritis that typically exhibits peak joint swelling at 24 hours post
induction with clinical symptoms and histopathological signs that resemble rheumatoid arthritis. Here,
MSC-derived EV treatments were administered concurrent with peak joint swelling and joint diameter was
measured daily up to day 3, and results were normalised to zero at day 1 peak joint swelling to minimise
the impact of variations between animals. We have previously shown that the intra-articular injection of
MSC conditioned medium in mice with AIA reduces joint swelling and histopathology (3). In this study, in
order to assess the contribution of EVs to the therapeutic effect of the MSC secretome, we compared EV
treatments to EV-depleted MSC conditioned medium, collected as described previously(3), and PBS only
vehicle controls, measuring the reduction of joint diameter from peak swelling (day 1) as a positive value.
Local administration of EVs into joints signi cantly reduced joint diameter, a measure of swelling.
Speci cally, EV-NormO2 (day 2 = 4.4 ± 0.6 mm, day 3 = 8.0 ± 0.6 mm, p < 0.01), EV-2%O2 (day 2 = 7.7 ± 
0.8 mm, day 3 = 11.0 ± 0.9 mm, p < 0.001) and EV-Pro-in am (day 2 = 6.7 ± 1.0 mm, day 3 = 11.3 ± 0.9 mm,
p < 0.001) all very signi cantly reduce joint swelling in comparison to PBS vehicle control treatments (day
2 = 0.2 ± 0.8 mm, day 3 = 2.8 ± 1.0 mm) (Fig. 2A). Histopathological analysis of joint damage which is
reported as arthritis index (AI) showed signi cantly reduced overall joint damage in mice treated with EV-
NormO2 (4.20 ± 0.79) and EV-Pro-In am (4.08 ± 1.04) compared to EV-depleted medium control (7.46 ± 
0.59). Whilst EV-2%O2 overall showed a tendency to reduce total AI scores (4.92 ± 0.84) compared to
controls, this was not statistically signi cant. For EV-NormO2, this reduced AI score re ected decreases
from control scores in hyperplasia of the synovial membrane (1.35 ± 0.22 vs 2.30 ± 0.17) and joint
exudate (0.50 ± 0.21 vs 1.68 ± 0.30), whilst EV-Pro-In am demonstrated reduced synovial in ltrate (2.0 ± 
0.39 vs 3.49 ± 0.24) (Fig. 2B).
Priming EVs does not affect expression of pro- (TNF-α) and
anti-in ammatory (IL-10) cytokines detectable in serum of
AIA mice
The pro-in ammatory cytokine TNF-α is a key driver of disease pathogenesis in RA and a therapeutic
target in biological treatments(39, 40). Conversely, IL-10 is a master regulator of anti-in ammatory
immune responses(7). Levels of TNF-α and IL-10 were measured at day 3 in the serum of mice following
EV treatments. However, levels of TNF-α in serum of treated mice did not vary signi cantly between
controls or treated conditions or between different treatment methodologies (Figure S1). ELISA on mouse
serum did not detect the presence of IL-10 in treatment or control conditions (data not shown).
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MSC-derived EVs reduce Th17 polarisation and restore the
Th17:Treg balance
To examine the mechanism by which MSC-derived EVs signi cantly reduced AIA severity, spleens and
lymph nodes (inguinal and popliteal) of EV-NormO2 and EV-depleted CM-MSC treated AIA mice and PBS
controls were dissociated, and CD4 + T cells isolated. Overall, EV-NormO2 did not increase the proportion
of CD4 + T cells in spleen (13.28 ± 0.51%) or lymph nodes (15.04 ± 1.04%) over PBS controls in spleen
(14.21 ± 1.07%) or lymph nodes (15.52 ± 1.15%). However, EV-depleted CM-MSC treatment resulted in a
statistically signi cant increase in CD4 + T cells in spleens (16.94 ± 0.81%, p < 0.05) compared to EV-
NormO2 treatment, but not in lymph nodes (Fig. 3A, 3B).
Next, isolated, in vivo primed CD4 + T cells were activated and cultured in vitro for 4 hours in the presence
of a membrane transport blocker. T cell polarisation was assessed by  ow cytometry analysis of
intracellular markers characteristic of Th1 (IFN-γ), Th2 (IL-4), Th17 (IL-17a) and regulatory T cells (CD25 
+ FOXP3+). In addition to the Th1/Th2 balance, the ratio of regulatory T cells (Tregs) to IL-17a expressing
CD4 + T cells (Th17) was examined as RA (and other autoimmune disease) sufferers experience an
imbalanced Th17:Treg ratio leading to inappropriate immune responses and tissue damage(41–44).
When compared to PBS control (3.23 ± 0.81%), spleen T cell polarisation towards Th17 effector cells
following both EV-NormO2 (0.83 ± 0.10%) and EV-depleted CM-MSC (0.90 ± 0.19%) treatments showed
signi cant decreases in the proportion of pro-in ammatory Th17 cells induced in AIA mice (n = 4, p < 
0.05), with no signi cant change in FOXP3 (Treg) proportions (Fig. 3C, 3D). This translated to a trend for
improved Treg:Th17 ratios in spleens of EV-NormO2 (12.06 ± 2.12:1) and EV-depleted CM-MSC (12.70 ± 
2.95:1) treated mice compared to PBS controls (5.03 ± 1.40:1, n = 4, p = 0.12, p = 0.09 respectively)
(Fig. 3E), despite an increase in pro-in ammatory Th1 cells in EV-NormO2 treated mice (6.38 ± 0.40%)
compared to PBS controls (4.00 ± 0.35%, p < 0.05, n = 4) (Fig. 3F). This result indicates that EVs can
prompt an advantageous shift in the Treg:Th17 balance towards a healthy state, demonstrating a similar
e cacy of applying EVs alone to that previously seen when applying CM-MSC(3). A similar trend was
seen in T cells from lymph nodes with a signi cant reduction in Th17 polarisation in EV (0.90 ± 0.09%)
and EV-depleted CM-MSC (0.93 ± 0.25%) compared with PBS controls (4.26 ± 1.12%, p < 0.05, n = 4)
(Fig. 3I) leading to improved Treg:Th17 ratio (Fig. 3J). Taken together, these data show that EV
treatments and EV-depleted medium were both capable of affecting alleviation of symptoms of
in ammatory arthritis through reduced Th17 polarisation and shift in the Treg:Th17 balance.
MSCs, not their EVs, enhance Th17 polarization when co-
cultured with CD4 + T cells
MSCs have been shown to deactivate T cells in co-culture (2, 3). With this in mind, in order to further
elucidate the in uence of MSC-derived EV treatments on T cell polarisation and proliferation, EV-NormO2,
EV-2%O2 and EV-Pro-In am were co-cultured with activated T cells isolated from healthy mice for 5 days.
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Cells were then examined for changes in CD4 + cell numbers and Th17 polarization. The ability of EV
treatments to affect deactivation of T cells and therefore in uence T cell proliferation was also examined.
MSC/CD4 + T cell co-cultures prompted signi cantly increased numbers of CD4 + T cells compared to EV
treatments or T cells alone (n = 3, p < 0.05) (Fig. 4A).
Further analysis of IL17a expressing cells within the CD4 + population demonstrated that MSC cultures
increased cell proportions in comparison to PBS controls, whereas all EV treatments showed a decrease
in Th17 cell polarisation (p > 0.05, n = 3) (Fig. 4B). IL-4 expressing Th2 cells were also elevated in MSC co-
cultures (6.00 ± 0.24%) compared to EV-Pro-In am (2.74 ± 0.52%) (p < 0.01, n = 3) but not in comparison
PBS control (4.79 ± 0.99%); EV-NormO2 (2.86 ± 0.30%) or EV-2%O2 (3.22 ± 0.03%) (p > 0.05, n = 3).
Additionally, the expression of IL17a per cell, represented by mean  uorescence intensity (MFI) of signal,
was signi cantly reduced in EV-NormO2 (3311.74 ± 33.71) and EV-2%O2/CD4 + T cell co-cultures
(3367.19 ± 39.92) compared to CD4 + T cells cultured alone (3728.69 ± 50.28) (p < 0.01, p < 0.05, n = 3)
(Fig. 4C). These results demonstrate that in vitro MSC-derived EVs do not prompt increases in CD4 + T cell
numbers or Th17 effector cell polarisation as seen with MSC treatments, suggesting a further advantage
in the therapeutic application of EVs over MSC.
MSCs, not their EVs, suppress T cell proliferation in co-
culture
We have previously shown the ability of MSCs to suppress T cell proliferation in co-culture, with MSCs
being more effective than CM-MSC(2, 3). Here, MSC/CD4 + T cell co-culture was included as a positive
control and, similarly to our previous observations, it reduced the proportion of proliferating T cells,
measured via a proliferative index and the number of proliferative cycles undergone by T cells in co-
culture (5.31 ± 0.38, 4.63 ± 0.17 respectively) in comparison to T cells cultured alone (6.16 ± 0.10, 5.44 ± 
0.25) (n = 8, p < 0.05). In contrast, CD4 + T cells showed no signi cant inhibition in proliferation when
cultured with EV-NormO2 (5.85 ± 0.08, 5.01 ± 0.17), EV-2%O2 (6.01 ± 0.18, 4.97 ± 0.14) or EV-Pro-In am
(6.28 ± 0.12, 4.95 ± 0.09) (n = 8, p > 0.05) (Fig. 4D). As seen previously with CM-MSC(3), EV treatments
showed greater impact on proliferative cycles than on the proliferative index, though treatments did not
signi cantly vary from either MSC co-cultures or T cells cultured alone, with the exception of pro-
in ammatory primed EVs which allowed a higher proliferative index in comparison to MSC co-culture (n = 
8, p < 0.05) (Fig. 4D). Together, this result, coupled with histological improvements, suggests that
suppression of T cell proliferation may not be the key mechanism for improved outcomes following
treatment in AIA.
Discussion
This study demonstrates the therapeutic e cacy of EVs as a treatment in the AIA model of in ammatory
arthritis. All EV treatments prompted amelioration of clinical symptoms of AIA with increased effect seen
in reduction of joint swelling when treated with EV-2%O2 or EV-Pro-In am. In line with this,
histopathological examination of the joints showed improved histological features following EV
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treatments compared to controls. Mechanistically, EVs acted remarkably different from their cells of
origin (MSCs) when co-cultured with CD4 + T cells from healthy spleens. EVs reduced Th17 polarization
without affecting T cell expansion and proliferation, while MSCs increased T cell expansion and Th17
polarization, and lessened T cell proliferation. Ex vivo, CD4 + T cells isolated from spleens of arthritic
mice treated with EVs showed signi cantly reduced Th17 polarization that rebalanced the Treg:Th17
ratio. Together, this suggests the reduction in Th17 cells, that led to restoration of the Treg:Th17 ratio
which is typically unbalanced in in ammatory arthritis, as the main therapeutic mode of action of MSC-
derived EVs.
To further dissect the therapeutic mechanism of action of MSC-derived EVs, circulating levels of TNF-α,
which is a key driver of pathogenesis in RA and therapeutic target in biological treatments, and IL-10,
which is a master regulator of anti-in ammatory immune responses, were measured in mice with AIA at
day 3. While IL-10 was not detected in our assay, similarly low levels of TNFa were detected in untreated
and EV-treated mice. This suggests that TNFa blockade and IL-10 modulation are not the mechanisms by
which MSC-derived EVs improve AIA and therefore EV treatment may represent an alternative option for
patients who do not respond to biological interventions such as anti-TNF therapy. Nevertheless, a wider
timecourse of serum TNF-α measurement (e.g. 14, 21 and 28 days) remains to be investigated.
Our previous study demonstrated reductions in Th17 cells following CM-MSC treatment compared to
control and MSC treatments. It also showed an increase in IL-10 expression and proportions of IL-4
expressing Th2 cells as well as cellular expression levels of IL-4 following MSC treatment(3). We also
demonstrated an improved Treg:Th17 effector cell ratio following CM-MSC treatment compared to MSC
treatments or controls(3). With these results in mind, the present study indicates that MSCs, not their
secretome, were driving increased IL-10 expression and were responsible for the reduction in Th1 and
increase in Th2 cells seen in our previous study. Remarkably, EVs, a component of the CM-MSC, are
capable of signi cantly reducing Th17 cell numbers. This represents a signi cant  nding in the search
for immunomodulatory therapeutics for treating autoimmune disorders where an imbalance in T cell
polarisation (Th1:Th2 or Treg:Th17) is integral in disease pathology. Moreover, EV treatment in this study
resulted in a highly improved (2.40-fold over controls) Treg:Th17 ratio compared to our previous results
using whole CM-MSC treatment (2.13-fold over control) or MSC treatment (1.47-fold over control) (3).
The normal ratios of Treg:Th17 cells can be calculated from previously published studies by looking at
proportions of either of these cell types in experimental investigations. The proportion of regulatory T
cells in a healthy human is commonly reported in the range of 2.3–4.9 ± 1.1%(45–50), and the proportion
of Th17 cells is reported at 0.50–2.13%(49–53) in peripheral blood, with typical murine Treg proportions
reported at 10.2–12.1% in spleens(45, 47, 48, 54, 55) and Th17 cells at 1.17% in spleens(47, 56)
respectively.
Therefore, using published research as above, a typical ratio of Treg:Th17 cells in healthy humans can be
estimated to range from 1.1:1 to 9.8:1 and in healthy mice from 6.0:1 to 7.1:1.
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In human RA sufferers the ratio of Treg:Th17 becomes imbalanced with peripheral blood Treg cells
ranging from 1.0 to 16.9%(41, 53, 57) and Th17 cells ranging from 0.91 to 0.96%(42, 51) in peripheral
blood, increasing to 2.20–9.09% in synovial  uid(42, 53). An analysis of published data from a range of
studies shows that RA sufferers experience a drop in FOXP3 + Tregs from 5.94 ± 1.40% in healthy
subjects to 4.44 ± 0.96% in patients, representing a 0.77 ± 0.07-fold decrease (p = 0.021, n = 17)(58).
These data can be analysed to demonstrate a Treg:Th17 ratio ranging from 1.0:1 to 18.6:1 in peripheral
blood and from 0.1:1 to 7.7:1 in synovial  uid of RA sufferers.
The proportions of Treg and Th17 cells in RA sufferers has been directly linked to the severity of disease,
and restoring the Treg:Th17 balance has the potential to promote homeostasis and positive clinical
outcomes by minimising in ammatory responses in a range of autoimmune disorders. Here, we
demonstrate that untreated (control) spleens of mice with AIA display a Treg:Th17 ratio of 5:1 that is
increased to 12:1 upon EV and EV-depleted CM-MSC treatments. This result reinforces the use of CM-
MSC as a therapeutic for RA, with EVs being a convenient and chemically de nable option for delivering
its therapeutic action. Furthermore, the data in this study and our previous research suggest that CM-MSC
might be a more effective therapeutic than MSCs for targeting in ammatory immune disorders such as
RA, whilst MSCs might be more suitable for the treatment of in ammatory disorders, including Crohn’s
Disease, Lyme’s arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, where tissue regeneration
and the Th1/Th2 balance are an issue(59). The concomitant rise in IL-4 expressing Th2 cells and IL-10 in
medium of MSC treatments but not CM-MSC seen previously would therefore be attributed to cellular
interactions rather than secretome components.
Th17 and Treg differentiation are antagonistic responses to TGF-β expression, with low levels of TGF-β
prompting synergy with IL6 and IL21 that in turn increases the expression of IL-23 receptor, resulting in
upregulation of Th17 cell production. Conversely, highly expressed TGF-β prompts naïve helper T cells to
express FOXP3 and retinoic acid receptor-related orphan receptor-γt (RORγt), and to repress the
expression of IL-23 receptor, thus tilting the balance towards the generation of Treg cells where RORγt
function is inhibited due to TGF-β induced FOXP3(60). Addition of IL-6, IL-21 and IL-23 restores RORγt
function and associated Th17 differentiation(60–62). In this regard, our results demonstrate inhibition of
IL17a production (or repressed IL-23 receptor expression) through EV treatment, inhibiting IL17a
production whilst leaving the induction of FOXP3 expressing Treg cells unaffected.
Here, EV treatments did not induce IL-10 production, indicating that MSC-derived EV do not mediate anti-
in ammatory effects via IL-10 as those seen in our previous study where MSCs and CM-MSC induced IL-
10 release upon co-culture with T cells(3). IL-10 functions to inhibit monocyte-derived cell production of
immunomodulatory cytokines such as IFN-γ and IL-4. This increases the likelihood that MSCs will convey
a greater impact on Th1 and Th2 expressing cells than their secretome alone(7). Additionally, IL-10
expression prevents dendritic cell tra cking to lymph nodes, which presents a hypothesis for MSC action
in reduced Th1 cell recruitment; however, here we demonstrate that lymph nodes show reductions only in
IL17a expressing Th17 cells when treated with EVs, in accordance with the lack of IL-10 expression in
medium previously shown (3).
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In vivo, dendritic cell EVs which are high in expression of intercellular adhesion molecule 1 (ICAM-1) show
high a nity binding to the surface of activated CD4 + T cells via the integrin leukocyte function-
associated antigen 1 (LFA-1) without the need for T cell receptor speci city(26). This recruitment enables
activated T cells to present acquired MHC class II peptide complexes from DCs and this can in uence the
activation and proliferation of the wider activated T cell population(63). MSCs are constitutively low in
ICAM-1 expression(64, 65) however these cells have been shown to upregulate expression of ICAM-1
when co-cultured with activated CD4 + T cells in response to the presence of increased pro-in ammatory
cytokine expression, leading to increased immunosuppressive properties of MSCs(64, 66). It follows then
that priming MSCs with pro-in ammatory cytokines will enhance T cell adhesion to secreted EVs through
increased binding e ciency and this has been shown to increase treatment potency(67, 68). It has been
suggested that the immunomodulatory properties of EVs are contingent on pro-in ammatory priming(21,
69). However, the present work demonstrates that alternative priming methodologies, namely hypoxia,
convey similarly enhanced immunosuppressive capabilities to secreted EVs.
Most studies utilise pro-in ammatory IFN-γ(70, 71) and/or TNF-α(72, 73) to facilitate priming, although
IL-1β(74) and IL-17a(75) have also been applied. Regardless of cytokine selection, the broad outcomes of
exposing cells in culture to a pro-in ammatory environment is to initiate strategies that would re-establish
homeostatic control in vivo, such as anti-in ammatory effects prompted through alteration of the EV
cargo(76) and signalling to reduce recruitment of in ammatory mediators, expression of pro-
in ammatory cytokines, T cell polarisation and proliferation(71, 72, 77), and restoration of homeostatic
ratios of leukocytes and T cells(73, 78). A primary mechanism involved here is IFN-γ-mediated
upregulation of indoleamine 2,3-dioxygenase (IDO)(70, 72, 73).
Our study demonstrates that pro-in ammatory priming of MSCs does indeed increase the e cacy of EVs
in treating in ammatory arthritis as observed in these studies. Our results suggest that the in vivo
response to pro-in ammatory primed EV treatment in the AIA model of in ammatory arthritis is not
primarily through inhibition of T cell proliferation, but through suppression of CD4 + Th17 effector
polarisation.
However, we also show that hypoxic priming of MSCs results in the production of EVs that alleviate joint
swelling as effectively as EVs secreted by MSCs primed with pro-in ammatory cytokines. This reduced
swelling by EV-2%O2 treatment did not translate to signi cant improvement in the  ne histological
structures assessed in our arthritis index. Conversely, whilst both EV-2%O2 and EV-Pro-In am treatments
inhibited polarisation of T cells towards pro-in ammatory Th17, EV-Pro-In am did not reduce the
expression levels of IL-17a in Th17 cells as seen in EV-2%O2 treatments. We hypothesise that whilst the
effectiveness of these treatment methodologies is similar in potency, the underlying mechanisms of
action differ. Interestingly, MSCs under hypoxic culture have been shown to promote anti-in ammatory
M2 macrophage polarization through a mechanism also dependent upon ICAM-1 adhesion(79), although
hypoxic MSCs exhibit reduced reactive oxygen species (ROS) levels and increased resistance to ROS
stress and upregulate secretion of growth factors and cytokines such as TGF-β, IL-8, IL-10 and PGE2,
which are also implicated in macrophage polarisation and MSC immunomodulatory capacity(36, 79, 80).
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Hypoxia inducible factor 1α (HIF-1α) is a primary sensor of hypoxia, and hypoxic conditions are
physiologically common in regions of in ammation(81). Reduced oxygen environments are
physiologically appropriate for MSCs resident in the bone marrow, where the available oxygen tensions
are equivalent to 1–9% dependent upon distance from the vasculature, with the MSC niche likely to be
resident in regions experiencing the lower end of this scale(36, 82). This makes EV-2%O2 a
physiologically relevant treatment option derived from healthy conditions. We see primarily Th17
immunomodulation through EV treatment. The underlying mechanism by which EV-2%O2 treatment
affects immunomodulation may be different to the mechanism(s) responsible for EV-Pro-In am-
mediated effects, yet both hypoxic and pro-in ammatory cytokine priming systems may converge in
affecting STAT3 activation. As described, RORγt is a master regulator of Th17 differentiation(60);
however, STAT3 induces RORγt expression and is activated by IL-6, IL-21 and IL-23, which are key
cytokines in promoting Th17 differentiation(60, 83). Moreover, STAT3 activation has been shown to be
mandatory for the development of Th17 cells and Th17 related autoimmunity, such as seen in RA, and an
absence of STAT3 activation inhibits Th17 formation and promotes Th1 differentiation through its
absence, skewing pro-in ammatory immune responses from Th17 to Th1(83). STAT3 has been
suggested as a therapeutic target in the treatment of autoimmune in ammatory disorders such as
RA(81). In normoxic conditions the HIF-1 gene is inhibited by proteasome mediated degradation of HIF-1α
and hydroxylation of HIF-1 by Factor Inhibiting HIF-1 protein (FIH)(84, 85). Hypoxia inhibits the function
of key hydroxylases, von-Hippel-Lindau (VHL)-ubiquitin ligase complexes that mark HIF-1α protein for
degradation in normoxia, and FIH. This in turn promotes increased HIF-1α protein in the cell due to
reduced catabolism in degradative processes(84). Hif-1α dimerization with HIF-1β in the nucleus leads to
transcriptional upregulation of genes in response to the hypoxia cues, primarily to drive metabolism from
oxidative phosphorylation and oxygen-dependent ATP production towards glycolytic energy metabolism
and decreased mitochondrial oxygen consumption. This reduces cellular dependency on oxygen,
alongside activity that will restore oxygen supply to an affected region, such as angiogenesis achieved
through regulation of target genes such as vascular endothelial growth factor (VEGF) and cathepsin D
(CTSD)(81, 84, 85).
Priming of MSCs with hypoxia activates HIF-1α and increases cell signalling to induce these shifts in
tissue energy metabolism and angiogenic responses to deal with the compromised in ammatory
environment. It therefore follows that treatment with hypoxically induced changes to signalling
molecules, such as EVs, conveys these coping mechanisms to the environment into which treatments are
induced, promoting tissue stabilisation and homeostasis into the diseased joint cavity. These effects, in
combination with enhanced immunomodulatory capacity due to increased TGF-β and IL-10 secretion and
reduction in ROS due to hypoxic culture, led us to hypothesise that this mechanism of action may be
more bene cial to cells. Prior exposure to pro-in ammatory cytokines prompt crisis responses in MSCs as
evidenced through the induced cell death following continued exposure to pro-in ammatory cocktails we
witnessed in our cell cultures if cytokine exposure exceeded 48 hours (data not shown).
Hypoxic culture of MSCs has been shown to aid maintenance of stemness and pluripotency in cells
whilst very low oxygen tensions can assist in maintaining quiescence in resident stem cells, which may
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be bene cial in clinical therapies dependent upon cell secretome rather than tissue regeneration(36). In
this study, we observed a trend for increased protein content in hypoxic EV preparations compared to pro-
in ammatory preconditioned cells, suggestive of a more potent EV treatment utilising this method of cell
priming, which more closely mimic the physiological microenvironment. Previous studies have also
demonstrated bene ts of hypoxic treatment of MSCs and cell therapies for tissue repair in regenerative
medicine treatments for arthritic disorders(86–93).
We have previously demonstrated CM-MSC reduced cartilage degradation by aggrecanase activity
through ADAMTS and MMPs cleavage3. RA disease manifests with increased circulating citrullinated
epitopes of degraded proteoglycans, including aggrecan, in > 60% of sufferers. This has implications in
the production of pro-in ammatory cytokines directly linked to increased Th17 polarisation(41, 42, 58,
59). Circulating MHC-II complexes with cartilage epitope fragments may be implicated in the
autoimmunity developed in RA through polarisation and activation of T cells, primarily Th17 effector
cells(63). MMP activation occurs in response to pro-in ammatory signalling(63), and EVs sourced from
stromal cells have been shown to carry both matrix metalloproteinases (MMPs), including MMP1, MMP2,
MMP3, MMP7, MMP9 and MMP10, and ADAM9, ADAM10 and ADAMTS12(94, 95), and also tissue
inhibitors of metalloproteinases (TIMPS) such as TIMP1, TIMP2 and TIMP3(94). Our previous study
provided evidence of reduced activity of catabolic enzymes following CM-MSC treatment even beyond
the effects seen with MSC infusion(3), thus the cargo of EVs may be the source of this mechanism of
action in CM-MSC tests. EVs may function as a source of inhibitors of aggrecanases or equally introduce
enzymes involved in epitope formation. As such, it would present an optimisation strategy to select EVs
that carry a cargo high in TIMPs and anti-in ammatory cytokines, and low in aggrecanases. This
presents a potential avenue for future investigation.
One common limitation in studies examining EVs is the presence of contaminating proteins present in
EVs isolation through ultracentrifugation(24). Given the knowledge that both hypoxic and pro-
in ammatory priming of MSCs can lead to increased expression of secreted proteins, it is important to
ascertain whether the effects seen here could be the result of EVs contamination with proteins that also
act to promote immunosuppression. In this study we utilised serum-free culture during EVs isolation to
eliminate protein or EV contaminations from serum, and we included a PBS wash step during 100,000G
ultracentrifugation to reduce residual protein. When measured, we saw no detectable IL-10 in T cell co-
cultures suggesting an absence of IL-10 contamination in EVs preparations.
In this study, our primary aim was to evaluate the e cacy of EV treatments in vivo during AIA. We show
that MSC priming leads to the release of EVs that if administered to mice with acute in ammatory
arthritis signi cantly ameliorate disease pathogenesis, mainly by inhibiting Th17 polarization. Future
studies will de ne the composition and sub-vesicular localisation of proteins in EV cargos.
Conclusions
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This study provides new evidence that supports the use of EVs in clinical therapies for RA and similar
autoimmune disorders. The possibility to manipulate the protein and nucleic acid cargo of EVs through
control of parental MSC cultures offers a novel opportunity for targeted therapies that can be tailored to
individual pathological features of RA, advancing personalised medicine. This study aims to support the
growing body of evidence for the introduction of EVs into the therapeutic milieu. Further work on the
control of EV cargo will elucidate the molecular mechanism of action and assist in the e cacy of cell-
based therapies in the clinic.
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Figure 1
Detailed characterisation of EVs. (A) Representative  ow cytometry analysis of EV-NormO2 preparations
using MACSPlex exosome detection kit (Miltenyi) for the detection of CD9 (mean 81.25±5.03); CD63
(mean 94.59±2.23); and CD81 (mean 79.41±9.07) with unstained control beads. (B) Western blotting
demonstrates presence of Alix and absence of cytochrome C in EVs (C) BCA assay assessment of total
protein concentration in EV preparations from normoxic (21%O2, n=11), hypoxic (2%O2, n=8) and pro-
in ammatory pre-conditioned MSC cultures (n=9), expressed as pg/mL per 1.0 x 106 cells. (D) (E)
Representative output from particle concentration and EV sizing Nanopore analysis (Izon) tuned in the
region ~80-300nm, highlighting EVs diameter range, with peak diameter averaging around 200nm with
maximal diameter around 500nm (n=11) (F) TEM characterisation of hBM-MSC derived small EVs. Small
EVs were re-suspended in sterile distilled water after isolation and spotted onto TEM grids before being
stained with uranyl acetate. Black arrows indicate recorded small EVs. Small EVs were isolated from
conditioned media taken from hBM-MSCs isolated from bone marrow aspirate cultured in hypoxic
conditions (EV-2%O2).
Page 28/31
Figure 2
MSC-derived EVs treatment of mice with AIA. (A) Alleviation of joint swelling as a measure of therapeutic
e cacy following EV treatments shows a signi cant effect of EVs compared to vehicle controls at day 2
and day 3 after arthritis induction; normalised to 0 at peak swelling (day 1). (B) Examination of
histological signs of arthritis pathogenesis following EV treatment shows signi cant therapeutic effects
of EVs sourced from MSCs cultured under normoxia and MSCs cultured in the presence of pro-
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in ammatory cytokines. (Control n=21, EV-NormO2 n=8, EV-2%O2 n=6, EV-Pro-In am n=6); *p<0.05,
**p<0.01, ***p<0.001.
Figure 3
Outcomes of intracellular staining for T cell polarisation analysis. Intracellular staining for FACS analysis
of IFN-γ, IL4 and IL17a in CD4+ T cells from EV-NormO2, EV-depleted CM-MSC or PBS control, showed
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signi cant reductions in IL17a expression suggestive of reduced Th17 polarisation and a restoration of
the Treg:Th17 balance in EV-NormO2 treated mice (n=4, *p<0.05).
Figure 4
Outcomes of EV treatments co-cultured with T cells isolated from healthy murine spleens (A) Increased
CD4+ Tcells in MSC co-cultures compared to EV-NormO2; EV-2%O2; EV-Pro-In am; and T cells alone
control (n=3; ***p<0.001) (B) Increased pro-in ammatory Th17 cells (IL17a+) in MSC co-cultures over to
EV-NormO2; EV-2%O2; EV-Pro-In am; and T cells alone control (n=3; ***p<0.001) (C) reduced expression
of IL17a in CD4+IL17a+ T cells in EV-NormO2 and EV-2%O2 co-cultures (n=3; *p<0.05; **p<0.01) (D) MSC
co-cultures signi cantly inhibited T cell proliferation compared with T cells cultured alone (both
measures) and EV-Pro-In am co-culture (Index of proliferation only) (n=3; *p<0.05).
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